PAEDS

The Paediatric Active Enhanced Disease Surveillance (PAEDS) network is a hospital-based active surveillance system employing prospective case ascertainment for selected serious childhood conditions, particularly vaccine preventable diseases and potential adverse events following immunisation (AEFI). PAEDS data is used to better understand these conditions, inform policy and practice under the National Immunisation Program, and enable rapid public health responses for certain conditions of public health importance. PAEDS enhances data available from other Australian surveillance systems by providing prospective, detailed clinical and laboratory information on children with selected conditions.

 
PAEDS aims:

  • to actively collect detailed information that isn’t available from other surveillance systems, about children hospitalised with vaccine-preventable diseases and potential adverse events following vaccination
  • to inform vaccination policy and practice, including vaccine safety
  • to improve child health outcomes.

 

PAEDS is a network of clinicians and public health researchers in six Australian tertiary paediatric hospitals which also works with several associate investigators, collaborators and contributors.  PAEDS is funded by the Australian Government Department of Health with contributions from the state health departments of New South Wales, Victoria, South Australia, Western Australia, Queensland and the Northern Territory. Funding from NHMRC grants also supplements certain surveillance activities. PAEDS is also under the oversight of the PAEDS Reference Group, composed of representatives from all participating Departments of Health and independent expert groups.

The conditions included in PAEDS are acute flaccid paralysis, intussusception, varicella and herpes zoster, pertussis, febrile seizures and acute childhood encephalitis.

Latest News

Evaluation of Combination Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Introduction in Australia

According to an evaluation which was carried out by the Paediatric Active Enhanced Disease Surveillance (PAEDS) in conjunction with The National Centre for Immunisation Research and Surveillance (NCIRS), the uptake of on-time measles-containing vaccinations has increased nationally by 13.5% over the last four years, since the MMRV vaccine was first introduced into the National Immunisation Program (NIP). The study also demonstrated that administration of MMRV vaccine as dose 2 of the measles-containing vaccine at age 18 months is not associated with an increased risk of febrile seizures.

Read more...